

Kevin Beja

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11616806/publications.pdf>

Version: 2024-02-01

19
papers

2,033
citations

471509

17
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

3173
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662.	7.0	52
2	Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1114-1125.	7.0	57
3	Activating <i>AKT1</i> and <i>PIK3CA</i> Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	1.9	47
4	Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	26
5	Genetic and Molecular Analysis of Essential Genes in Centromeric Heterochromatin of the Left Arm of Chromosome 3 in <i>Drosophila melanogaster</i> . <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 1581-1595.	1.8	7
6	A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 201-208.e1.	1.9	29
7	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	1.9	131
8	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. <i>Cancer Discovery</i> , 2018, 8, 444-457.	9.4	376
9	Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancer. <i>Communications Biology</i> , 2018, 1, 122.	4.4	21
10	Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. <i>Lab on A Chip</i> , 2018, 18, 1736-1749.	6.0	21
11	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	1.9	179
12	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	9.4	223
13	Genome-wide chemical mapping of O-GlcNAcylated proteins in <i>Drosophila melanogaster</i> . <i>Nature Chemical Biology</i> , 2017, 13, 161-167.	8.0	33
14	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6802-6811.	7.0	69
15	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	7.0	121
16	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	288
17	SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA. <i>Bioinformatics</i> , 2017, 33, 26-34.	4.1	48
18	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1598.	7.1	290

#	ARTICLE	IF	CITATIONS
19	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e233-e236.	1.9	15